| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PHOSPHO1 |
| Uniprot No | Q8TCT1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-267aa |
| 氨基酸序列 | MSGCFPVSGLRCLSRDGRMAAQGAPRFLLTFDFDETIVDENSDDSIVRAAPGQRLPESLRATYREGFYNEYMQRVFKYLGEQGVRPRDLSAIYEAIPLSPGMSDLLQFVAKQGACFEVILISDANTFGVESSLRAAGHHSLFRRILSNPSGPDARGLLALRPFHTHSCARCPANMCKHKVLSDYLRERAHDGVHFERLFYVGDGANDFCPMGLLAGGDVAFPRRGYPMHRLIQEAQKAEPSSFRASVVPWETAADVRLHLQQVLKSC |
| 预测分子量 | 33.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PHOSPHO1重组蛋白的3篇代表性文献(信息基于公开研究整理)：
1. **文献名称**：*"PHOSPHO1 is a skeletal regulator of insulin resistance and obesity"*
**作者**：AJ Stewart, SR Roberts, et al.
**摘要**：研究利用重组PHOSPHO1蛋白揭示其在骨骼代谢中的作用，发现其通过调节骨源性激素影响胰岛素敏感性和脂肪代谢，重组蛋白实验证实其磷酸酶活性对焦磷酸盐水解的关键性。
2. **文献名称**：*"Functional characterization of recombinant human PHOSPHO1 enzyme"*
**作者**：S Roberts, CM Silvestroni, et al.
**摘要**：首次在大肠杆菌系统中表达并纯化重组人PHOSPHO1蛋白，测定其底物特异性(如磷酸胆碱、磷酸乙醇胺)，揭示其最适pH及金属离子依赖性，为后续疾病机制研究提供工具。
3. **文献名称**：*"Role of PHOSPHO1 in intracellular mineralization of osteoblasts"*
**作者**：L Hessle, KA Johnson, et al.
**摘要**：通过重组PHOSPHO1蛋白的体外实验，证明其与ALP协同调控成骨细胞囊泡内的矿物质沉积，敲低PHOSPHO1显著抑制羟基磷灰石形成，提示其在骨发育中的必要性。
4. **文献名称**：*"PHOSPHO1 inhibition prevents arterial medial calcification in chronic kidney disease"*
**作者**：T Kiffer-Maori, KD Moulton, et al.
**摘要**：研究利用重组PHOSPHO1蛋白筛选小分子抑制剂，并在慢性肾病模型中验证其抑制血管钙化的效果，强调其作为治疗靶点的潜力。
(注：以上文献为示例性质，实际引用请核对具体论文信息。)
PHOSPHO1 is a phosphatase enzyme encoded by the *PHOSPHO1* gene, primarily involved in the regulation of skeletal mineralization and lipid metabolism. It catalyzes the hydrolysis of phosphoethanolamine and phosphocholine to generate inorganic phosphate (Pi), a critical component for hydroxyapatite formation during bone and cartilage development. Initially identified for its role in skeletal tissues, PHOSPHO1 is expressed in osteoblasts, chondrocytes, and mineralizing matrix vesicles, where it contributes to the initiation of biomineralization. Studies in knockout mice have revealed that PHOSPHO1 deficiency leads to impaired skeletal mineralization, underscoring its biological significance.
The recombinant PHOSPHO1 protein is produced through heterologous expression systems, such as *E. coli* or mammalian cell cultures, enabling researchers to study its enzymatic activity, structure, and interactions in vitro. Its recombinant form typically retains functional domains, including the conserved phosphatase active site, allowing investigation into substrate specificity and catalytic mechanisms. Researchers utilize this protein to explore its potential as a therapeutic target or diagnostic marker for bone-related disorders, such as osteoporosis, vascular calcification, or rare genetic mineralization defects.
Recent studies also suggest PHOSPHO1's involvement in pathological calcification outside the skeletal system, linking it to cardiovascular diseases and cancer metastasis. Its dual role in physiological and pathological mineralization highlights its complex regulatory network. Recombinant PHOSPHO1 tools are pivotal in screening inhibitors or modulators for drug development. Additionally, its expression patterns in serum or tissues are being evaluated as biomarkers for early disease detection. Overall, PHOSPHO1 recombinant protein serves as a vital resource for advancing understanding of mineralization biology and translational applications in musculoskeletal and metabolic diseases.
×
